Connect Biopharma Holdings Limited
NASDAQ · us_market
No AI insight generated yet for this ticker.
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-03-31 | -0.30 | -0.27 | +10.00% |
| 2025-11-12 | -0.23 | -0.31 | -31.91% |
| 2025-08-13 | -0.22 | -0.23 | -4.55% |
| 2025-05-15 | -0.26 | -0.19 | +26.92% |
| 2022-09-12 | -0.51 | -0.53 | -3.47% |
| 2022-03-31 | -0.52 | -0.50 | +3.66% |
| 2022-03-30 | -0.48 | -0.50 | -3.74% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| CNTB | +0.81% | +0.40% | -11.70% | +196.43% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -2.16% | +5.04% | -8.26% | +183.74% |